CNS Pharma: Rises on achieving milestones for lead tumor treatment

CNS Pharmaceuticals

03/09/2020 16:36

** Shares of the biotech company  CNSP.O  rise 11% to $2.19;
stock among biggest pct gainers across U.S. indexes
    ** Co has completed synthesis of active pharmaceutical
ingredient (API) for its lead treatment for brain and spinal
cord tumor, Berubicin  urn:newsml:reuters.com:*:nPn2M9GPza
    ** CNSP has shipped the API to two manufacturers to make an
injectable form of Berubicin for clinical use
    ** Co has manufacturing deals with U.S.-based Pharmaceutics
International and Italy-based BSP Pharmaceuticals
    ** CNSP expects to start making the treatment at
Pharmaceutics in Q3 and plans to submit application to begin
human trials in Q4
    ** CNS and Pharmaceutics have also agreed on the
manufacturing procedure and packaging components for Berubicin
and selected a sterile filter manufacturer
    ** CNSP fell 44.3% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))